person · Reporting owner

KLEIN JOSEPH III

Disclosed activity across 2 companies

Tapewire entity: 32405
SEC CIK: 0001206369

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
IONIS PHARMACEUTICALS INCIONS · Entity 1182	Director	July 01, 2026	July 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IONIS PHARMACEUTICALS INC

Report date July 01, 2026 · Filed July 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,014	Ending reported balance After 2026-07-01 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-07-01 · Exercise / conversion · Acquired 11,518 · Balance 22,532 Row 2 · 2026-07-01 · Sale · Disposed 99 · Balance 22,433 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. Row 3 · 2026-07-01 · Sale · Disposed 11,419 · Balance 11,014 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.39 to $79.38 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.94 · Expires 2035-06-30	Direct	0	Reported balance After 2026-07-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-07-01 · Exercise / conversion · Disposed 11,518 · Balance 0
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.19 · Expires 2036-06-30	Direct	5,369	Reported balance After 2026-07-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-07-01 · Grant · Acquired 5,369 · Balance 5,369 F4: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F5: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	16,277	Reported balance After 2026-07-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-07-01 · Grant · Acquired 2,301 · Balance 16,277 F6: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F7: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026.
Common StockSEC Table I · non-derivative	Indirectby Son	200	Reported balance Holding disclosure · report date 2026-07-01 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 200 F3: The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.39 to $79.38 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

F3: The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F4: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F5: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026.

F6: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AKCEA THERAPEUTICS, INC.

Report date October 12, 2020 · Filed October 13, 2020

Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.14 · Expires 2030-04-12	Direct	0	Reported balance After 2020-10-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-10-12 · Disposition to issuer · Disposed 26,400 · Balance 0 F1: This option, which provided for vesting of the shares on the 12-month anniversary of the date of grant, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.

Filing footnotes · ownership attribution and instrument terms

F1: This option, which provided for vesting of the shares on the 12-month anniversary of the date of grant, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 03, 2024 Filed May 7, 2024 20:55 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	1,070	$42.55	$45,525.61	Disclosure SEC source: 0000874015-24-000144 · edgardoc.xml · nonDerivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 930 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.36 to $42.79 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document
May 03, 2024 Filed May 7, 2024 20:55 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	731	$42.98	$31,415.97	Disclosure SEC source: 0000874015-24-000144 · edgardoc.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 2,000 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.54 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) on this Form 4. Read SEC document
May 03, 2024 Filed May 7, 2024 20:55 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	1,269	$42.59	$54,043.54	Disclosure SEC source: 0000874015-24-000144 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 2,731 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.36 to $42.77 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document
May 03, 2024 Filed May 7, 2024 20:55 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	682	$42.94	$29,288.42	Disclosure SEC source: 0000874015-24-000144 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 4,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.80 to $43.54 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document
May 03, 2024 Filed May 7, 2024 20:55 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	1,318	$42.57	$56,110.03	Disclosure SEC source: 0000874015-24-000144 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 4,682 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.36 to $42.79 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document
November 15, 2023 Filed Nov 17, 2023 21:58 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	2,000	$50.00	$100,000.00	Disclosure SEC source: 0000874015-23-000211 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,346 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 17, 2022 Read SEC document
September 26, 2023 Filed Sep 28, 2023 22:03 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	2,000	$45.13	$90,253.60	Disclosure SEC source: 0000874015-23-000196 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,346 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 17, 2022 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.05 to $45.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4 Read SEC document
July 18, 2023 Filed Jul 19, 2023 22:05 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	3,555	$42.00	$149,310.00	Disclosure SEC source: 0000874015-23-000176 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,346 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 17, 2022 Read SEC document
July 17, 2023 Filed Jul 19, 2023 22:05 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Unit · Derivative	5,333	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-23-000176 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,677 Underlying: Common Stock · 5,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F6 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 17, 2023 Filed Jul 19, 2023 22:05 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Unit · Derivative	1,777	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-23-000176 · edgardoc.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,010 Underlying: Common Stock · 1,777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 17, 2023 Filed Jul 19, 2023 22:05 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	5,333	$0.00	$0.00	Disclosure SEC source: 0000874015-23-000176 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document
July 17, 2023 Filed Jul 19, 2023 22:05 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	1,777	$0.00	$0.00	Disclosure SEC source: 0000874015-23-000176 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document
July 03, 2023 Filed Jul 6, 2023 21:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Unit · Derivative	4,677	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-23-000158 · edgardoc.xml · derivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,787 Underlying: Common Stock · 4,677 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2023 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4 · derivative.exercise_date: Grant of Restricted Stock Unit award on July 3, 2023 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 3, 2023 F4 · derivative.expiration_date: Grant of Restricted Stock Unit award on July 3, 2023 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 3, 2023 Read SEC document
July 03, 2023 Filed Jul 6, 2023 21:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantNon-Qualified Stock Option (right to buy) · Derivative	10,321	$0.00 Strike: $41.08	$0.00	Disclosure SEC source: 0000874015-23-000158 · edgardoc.xml · derivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,321 Underlying: Common Stock · 10,321 shares Expires 2033-07-02 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2023 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 3, 2023 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 3, 2023. F2 · derivative.expiration_date: Grant on July 3, 2023 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 3, 2023. Read SEC document
January 17, 2023 Filed Jan 19, 2023 01:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	2,000	$40.00	$80,000.00	Disclosure SEC source: 0000874015-23-000046 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,791 F1 · kind: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 17, 2022 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 17, 2022 Read SEC document
July 15, 2022 Filed Jul 19, 2022 23:20 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Unit · Derivative	2,665	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-22-000140 · edgardoc.xml · derivative · entry 8 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 2,665 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F9 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F9 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 15, 2022 Filed Jul 19, 2022 23:20 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Unit · Derivative	5,333	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-22-000140 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,775 Underlying: Common Stock · 5,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F8 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F8 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 15, 2022 Filed Jul 19, 2022 23:20 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	644	$38.78	$24,974.32	Disclosure SEC source: 0000874015-22-000140 · edgardoc.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,791 F3 · kind: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020. F3 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.44 to $39.23 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) on this Form 4. Read SEC document
July 15, 2022 Filed Jul 19, 2022 23:20 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	689	$37.74	$26,002.86	Disclosure SEC source: 0000874015-22-000140 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,435 F3 · kind: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020. F3 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.26 to $38.225 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document
July 15, 2022 Filed Jul 19, 2022 23:20 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	2,665	$0.00	$0.00	Disclosure SEC source: 0000874015-22-000140 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F2 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document
July 15, 2022 Filed Jul 19, 2022 23:20 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	5,333	$0.00	$0.00	Disclosure SEC source: 0000874015-22-000140 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document
July 01, 2022 Filed Jul 6, 2022 21:25 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Unit · Derivative	5,333	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-22-000122 · edgardoc.xml · derivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,108 Underlying: Common Stock · 5,333 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Grant on July 1, 2022 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2022. F3 · derivative.expiration_date: Grant on July 1, 2022 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2022. Read SEC document
July 01, 2022 Filed Jul 6, 2022 21:25 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $38.06	$0.00	Disclosure SEC source: 0000874015-22-000122 · edgardoc.xml · derivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-06-30 F1 · derivative.exercise_date: Grant on July 1, 2022 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2022. F1 · derivative.expiration_date: Grant on July 1, 2022 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2022. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftNon-Qualified Stock Option (right to buy) · Derivative	8,000	$0.00 Strike: $64.80	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · derivative · entry 15 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-06-30 F3 · kind: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F3 · shares: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $60.20	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · derivative · entry 14 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-30 F3 · kind: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F3 · shares: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftNon-Qualified Stock Option (right to buy) · Derivative	16,000	$0.00 Strike: $57.16	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · derivative · entry 13 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2025-06-30 F3 · kind: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F3 · shares: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftNon-Qualified Stock Option (right to buy) · Derivative	16,000	$0.00 Strike: $52.22	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · derivative · entry 12 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-07-02 F3 · kind: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F3 · shares: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $42.88	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · derivative · entry 11 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-07-01 F3 · kind: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F3 · shares: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $24.42	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · derivative · entry 10 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2026-06-30 F3 · kind: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F3 · shares: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftNon-Qualified Stock Option (right to buy) · Derivative	8,000	$0.00 Strike: $64.80	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · derivative · entry 9 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-06-30 F3 · kind: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F3 · shares: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F5 · derivative.exercise_date: Grant of 7/1/19 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, with the first installment vesting on 7/1/20. The option shall be fully vested and exercisable on 7/1/23. The option was exercisable as to 8,000 shares on 11/30/21. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $60.20	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · derivative · entry 8 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2030-06-30 F3 · kind: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F3 · shares: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftNon-Qualified Stock Option (right to buy) · Derivative	16,000	$0.00 Strike: $57.16	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2025-06-30 F3 · kind: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F3 · shares: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftNon-Qualified Stock Option (right to buy) · Derivative	16,000	$0.00 Strike: $52.22	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2027-07-02 F3 · kind: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F3 · shares: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $42.88	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · derivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 12,000 shares Expires 2028-07-01 F3 · kind: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F3 · shares: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F4 · derivative.exercise_date: Grant of 7/2/18 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, with the first installment vesting on 7/2/19. The option shall be fully vested and exercisable on 7/2/22. The option was exercisable as to 12,000 shares on 11/30/21. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $24.42	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · derivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-06-30 F3 · kind: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F3 · shares: The reported transactions reflect the gift of vested stock options to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftCommon Stock	6,000	$0.00	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,000 F1 · kind: The reported transaction reflects the gift of shares to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F1 · shares: The reported transaction reflects the gift of shares to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. Read SEC document
November 30, 2021 Filed Feb 14, 2022 23:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GiftCommon Stock	6,000	$0.00	$0.00	Disclosure SEC source: 0000874015-22-000074 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,126 F1 · kind: The reported transaction reflects the gift of shares to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. F1 · shares: The reported transaction reflects the gift of shares to trusts for the benefit of the reporting person's three children, of which the reporting person's wife is a trustee. Read SEC document
July 15, 2021 Filed Jul 20, 2021 00:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Unit · Derivative	1,778	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-21-000136 · edgardoc.xml · derivative · entry 10 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,775 Underlying: Common Stock · 1,778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 15, 2021 Filed Jul 20, 2021 00:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Unit · Derivative	666	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-21-000136 · edgardoc.xml · derivative · entry 9 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,553 Underlying: Common Stock · 666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 15, 2021 Filed Jul 20, 2021 00:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Unit · Derivative	889	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-21-000136 · edgardoc.xml · derivative · entry 8 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,219 Underlying: Common Stock · 889 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 15, 2021 Filed Jul 20, 2021 00:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Unit · Derivative	5,333	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-21-000136 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,108 Underlying: Common Stock · 5,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F6 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 15, 2021 Filed Jul 20, 2021 00:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	4,334	$35.30	$152,989.33	Disclosure SEC source: 0000874015-21-000136 · edgardoc.xml · nonDerivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,126 F2 · kind: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020. F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.78 to $35.68 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document
July 15, 2021 Filed Jul 20, 2021 00:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	1,778	$0.00	$0.00	Disclosure SEC source: 0000874015-21-000136 · edgardoc.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award. Read SEC document
July 15, 2021 Filed Jul 20, 2021 00:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	666	$0.00	$0.00	Disclosure SEC source: 0000874015-21-000136 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award. Read SEC document
July 15, 2021 Filed Jul 20, 2021 00:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	889	$0.00	$0.00	Disclosure SEC source: 0000874015-21-000136 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award. Read SEC document
July 15, 2021 Filed Jul 20, 2021 00:14 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	5,333	$0.00	$0.00	Disclosure SEC source: 0000874015-21-000136 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award. Read SEC document
July 01, 2021 Filed Jul 6, 2021 21:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Unit · Derivative	5,333	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-21-000114 · edgardoc.xml · derivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,441 Underlying: Common Stock · 5,333 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Grant of July 1, 2021 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2021. F3 · derivative.expiration_date: Grant of July 1, 2021 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2021. Read SEC document
July 01, 2021 Filed Jul 6, 2021 21:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $40.05	$0.00	Disclosure SEC source: 0000874015-21-000114 · edgardoc.xml · derivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: Grant of July 1, 2021 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2021. F1 · derivative.expiration_date: Grant of July 1, 2021 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2021. Read SEC document
October 20, 2020 Filed Oct 22, 2020 21:36 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	2,889	$46.86	$135,385.76	Disclosure SEC source: 0000874015-20-000138 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,794 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.33 to $47.15, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4 Read SEC document
October 12, 2020 Filed Oct 13, 2020 19:37 UTC	AKCEA THERAPEUTICS, INC. AKCA · Entity 145982	Disposition to issuerStock Option (right to buy) · Derivative	26,400	$2.01 Strike: $16.14	$53,064.00	Disclosure SEC source: 0001209191-20-054608 · doc4.xml · derivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,400 shares Expires 2030-04-12 F1 · derivative.exercise_date: This option, which provided for vesting of the shares on the 12-month anniversary of the date of grant, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.